India Cracks Down on Unlicensed Weight-Loss Drug Sales

The Drugs Controller General of India (DCGI) has significantly ramped up regulatory surveillance to ensure ethical pharmaceutical practices concerning GLP-1 class weight-loss drugs. This intensified action follows concerns over the on-demand availability of these medications through various channels, including retail pharmacies, online platforms, and wellness clinics.

Inspections and audits have been conducted across multiple regions at 49 entities, such as online pharmacy warehouses, drug wholesalers, retailers, and slimming clinics. These efforts aim to identify and prevent unauthorized sales, improper prescription practices, and misleading marketing of these drugs. The DCGI, in collaboration with state regulators, has issued advisories against surrogate advertisements and any promotional activity that could mislead consumers or encourage off-label usage.

Patient safety remains the foremost priority, with the regulator stressing that GLP-1 weight-loss drugs carry serious health risks if used without clinical oversight. These medications are approved in India only with prescription from specialists like endocrinologists, internal medicine physicians, or cardiologists for specific indications. Non-compliance with regulations will be met with strict actions, including license cancellation, penalties, and legal prosecution.